DiscGenics, Inc.

23 articles with DiscGenics, Inc.

• DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

   DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chief Executive Officer and Chairman Flagg Flanagan will present at the 40th Annual J.P. Morgan Healthcare Conference.

• 

  Clinical Catch-Up: April 26-30

  5/3/2021

  Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.

• DiscGenics Raises $50 Million in Series C Funding

  8/25/2020

  DiscGenics, Inc. , a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has raised $50 million in a Series C funding round led by Ci:z Investment LLP with participation from new inves

• 

  Clinical Catch-Up: March 2-6

  3/9/2020

  It was a relatively quiet week for clinical trial announcements. Here’s a look.

• DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease

  3/4/2020

  DiscGenics, Inc. , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT

• 

  Clinical Catch-Up: October 28-Nov 1

  11/4/2019

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

• DiscGenics' U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark

  9/16/2019

  DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been safely treated its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD

• DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration

  8/26/2019

  Fast Track is a special regulatory designation that companies can apply for once they have sufficient preclinical and clinical evidence that a product may be able to treat an unmet medical need for a serious medical condition.

• DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease

  8/7/2019

  The treatments took place at Tokai University School of Medicine in Kanagawa, led by Dr. Daisuke Sakai, Associate Professor at the Department of Orthopaedic Surgery and the study's principal investigator.

• DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

  1/7/2019

  DiscGenics, Inc. announced that IDCT has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease

• DiscGenics Receives Approval from Japanese Pharmaceuticals and Medical Devices Agency to Begin Clinical Evaluation of Non-Surgical Degenerative Disc Disease Treatment in Japan

  12/11/2018

  DiscGenics, Inc. today announced the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved a Clinical Trial Notification (CTN) application for IDCT, an allogeneic injectable disc cell therapy for the treatment of degenerative disc disease (DDD).

• DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

  4/26/2018

  DiscGenics, Inc. announced the first patient has been treated in its phase I/II U.S. clinical trial of IDCT for mild-to-moderate degenerative disc disease (DDD).

• DiscGenics Presents Promising Preclinical Study Results at ORS 2018

  3/22/2018

  DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has presented results from two preclinical studies of IDCT at the Orthopedic Research Society (ORS) 2018 Annual Meeting, which was held last week in New Orleans, LA.

• DiscGenics Joins MedCision's ThawSTAR Early Adopter Program for Cell Therapy Clinical Trials

  11/1/2017

  The program was initiated to help companies and investigators de-risk thawing of frozen cell therapies in early stage clinical trials through to commercialization and point-of-care.

• DiscGenics, Inc. Receives FDA Allowance Of IND To Commence Clinical Study Of Its Degenerative Disc Disease Therapy

  10/3/2017

• DiscGenics, Inc. Raises $14 Million In Series B Financing

  9/26/2017

• DiscGenics, Inc. Fortifies Its Intellectual Property Portfolio With 9 Additional Patents

  11/3/2016

• DiscGenics, Inc. Recognized As Top 100 Company In North America By Red Herring

  5/21/2014

• BioLife Solutions, Inc. CryoStor® Adopted by DiscGenics, Inc. For Use In Novel, Injectable Cellular Therapy For Degenerative Disc Disease

  12/9/2013

• Dr. Kevin Foley to Present DiscGenics, Inc.'s Recent Findings at the Lumbar Spine Research Society's Annual Meeting

  4/3/2013